Inspirna is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Inspirna's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016.
Location: United States, New York
Employees: 11-50
Total raised: $50M
Founded date: 2010
Investors 4
Date | Name | Website |
20.12.2021 | Exor | exor.com |
- | K2 HealthV... | k2healthve... |
07.07.2022 | Vivo Capit... | vivocapita... |
- | K2 HealthV... | k2hv.com |
Funding Rounds 1
Date | Series | Amount | Investors |
11.07.2022 | Series D | $50M | - |
Mentions in press and media 4
Date | Title | Description | Source |
04.01.2024 | Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Ac... | - | vivocapita... |
12.07.2022 | Exclusive: Lightspeed raises $7.1B across four funds and for... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
11.07.2022 | Inspirna Scoops Up $50M Series D Round | NEW YORK, NY, Inspirna announced that it has raised $50 million in a Series D financing round. &g... | vcnewsdail... |
11.07.2022 | Inspirna Raises $50M in Series D Financing | Inspirna, a New York-based clinical stage biopharmaceutical company, raised $50M in Series D funding... | finsmes.co... |